… pathway inhibition might be a potential strategy. In the current outbreak, we need to understand
which patients might benefit from treatment with such cytokine inhibitors … inhibitors, which …

… COVID-19 patients, it is crucial to further explore selective cytokine blockade with drugs like
the IL-6 inhibitors … the downstream IL-6 signaling pathways, which can lead to decreased cell …

… , such as COX-2 inhibitors/TP antagonists, can be an innovative treatment to control the
overall … on AA pathway implication in COVID-19 can contribute in developing new therapeutic …

… interest for the treatment of COVID-19. Lopinavir is a protease inhibitor with high specificity
for … Since tocilizumab seems able to prevent the hyperactivation of inflammatory pathway, its …

… toxicities of potential therapeutics for COVID-19 and possible treatments for those toxicities.
This … and hydroxychloroquine inhibit the Toll-like receptor (TLR) pathway; the TLR pathway is …

… therapeutic developments against SARS-CoV-2 are depicted along with an overview of effective
management of post COVID-19 … help to treat COVID-19 is by inhibition of viral replication…

… This evidence shows that CD147 can be a novel route for the infection of SARS-CoV-2 as
… cyclophilin inhibitors and therapies on coronaviruses, especially COVID-19. However, as a …

… signaling pathway) in seriously affected COVID patients and … to block both of its signaling
pathway. One of this molecule, … IL-6) and can inhibit both classical and trans signaling pathway (…

… Neutrophils release the serine protease neutrophil elastase, which inhibits tissue factor
pathway inhibitor and leads to generation of thrombin, the most potent activator of platelets. …

… act via the JAK-2 and JAK-2 signal transducers with subsequent activation of STAT pathway.
Hence, JAK-inhibitors ruxolitinib and baricitinib have been employed to treat moderate-to-…